Oxurion NV ( OXUR.BR) Stock. Should you Buy or Sell? $ 0.32
0.01 (4.23 %)
Oxurion NV Analysis
Updated on 08-08-2022
| Symbol |
OXUR.BR |
| Price |
$0.32 |
| Beta |
0.889 |
| Volume Avg. |
$197.49 thousand |
| Market Cap |
$16.25 M |
| 52 Week Range |
$0.285 - $2.59 |
Oxurion NV opened the day at $0.32 which is +'4.23 % on yesterday's close.
Oxurion NV has a 52 week high of $2.59 and 52 week low of $0.285, which is a difference of $2.305.
We like to see positive, upward trending shares, preferably with momentum.
Market capitalization is $16.25 M and total net profit is $1128000 which means the company is trading at 14.41 times profit to market capitalization. Theoretically, if you were to buy Oxurion NV for $16.25 M, it would take 15 years to get your money back. Oxurion NV are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
1 D | All
Financials
Oxurion NV Stock Forecast - Is Oxurion NV a Buy or Sell?
| DCF Score | | Strong Buy |
| ROE Score | | Sell |
| ROA Score | | Sell |
| DE Score | | Neutral |
| PE Score | | Strong Sell |
| PB Score | | Strong Buy |
| Overall Recommendation | | Neutral |
Growth and Value
| PE Ratio |
-0.250 |
| Dividend Yiel |
0.000 |
| Net Profit Margin |
-11.304 |
Valuing Oxurion NV
| Price Book Value Ratio |
-11.260 |
Price To Book Ratio |
-11.260 |
| Price To Sales Ratio |
2.830 |
Price Earnings Ratio |
-0.250 |
How liquid is Oxurion NV
| Current Ratio |
1.229 |
| Quick Ratio |
0.915 |
Debt
| Debt Ratio |
1.059 |
Debt Equity Ratio |
-18.538 |
| Long Term Debt To Capitalization |
1.146 |
Total Debt To Capitalization |
1.098 |
Latest news about Oxurion NV
About Oxurion NV
CEO : Dr. Patrik De Haes
Sector : Healthcare
Industry : Biotechnology
Website : https://www.oxurion.com
Description :
Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.
